Cambridge, MA, July 27, 2026
Insilico Medicine has announced that first-in-human Phase 1 clinical trial data for ISM6331, its AI-designed pan-TEAD inhibitor, has been accepted for a Rapid Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2026. The presentation highlights a significant milestone for the company’s generative AI-powered drug discovery platform and underscores growing momentum in the development of innovative targeted therapies for mesothelioma and other advanced solid tumors. Scheduled for presentation during ESMO 2026 in Madrid, Spain, the study will showcase early clinical findings from a global multicenter Phase 1 trial evaluating the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of ISM6331, a novel small-molecule inhibitor targeting the Hippo signaling pathway. The selection for a Rapid Oral Presentation recognizes the scientific importance of the investigational therapy and reinforces Insilico Medicine’s leadership in applying artificial intelligence to accelerate oncology drug discovery.
First-in-Human Phase 1 Study Highlights Clinical Progress
The Rapid Oral Presentation will feature results from the ongoing first-in-human multicenter Phase 1 clinical trial of ISM6331 in patients with malignant mesothelioma and other advanced solid tumors. The study is designed to evaluate the investigational therapy’s safety, tolerability, pharmacokinetics, and preliminary efficacy, while supporting dose optimization for future clinical development. Patients enrolled in the trial represent cancers driven by abnormalities in the Hippo signaling pathway, an important regulator of tumor growth, tissue homeostasis, and therapeutic resistance. According to Insilico Medicine, the presentation at ESMO 2026 marks an important clinical milestone that provides early evidence supporting the continued advancement of ISM6331 as a potential targeted treatment option for patients with limited therapeutic alternatives. The acceptance of the study for one of oncology’s most prestigious scientific meetings further demonstrates the growing interest in AI-enabled drug discovery and innovative approaches to treating difficult-to-manage solid tumors.
AI-Designed Pan-TEAD Inhibitor Targets the Hippo Pathway
ISM6331 is a novel, potent small-molecule pan-TEAD inhibitor discovered and designed using Insilico Medicine’s proprietary Chemistry42 generative AI platform. The therapy selectively targets TEAD transcription factors, the primary downstream effectors of the Hippo signaling pathway, which plays a central role in regulating cell proliferation, survival, tissue regeneration, and resistance to cancer therapies across multiple tumor types. While the Hippo pathway has long been recognized as a promising therapeutic target, developing effective small-molecule TEAD inhibitors has remained a major medicinal chemistry challenge. By leveraging generative artificial intelligence, Insilico Medicine successfully designed ISM6331 to overcome these challenges and advance the compound into global clinical development. Company leadership noted that the ESMO presentation validates both the scientific potential of ISM6331 and the ability of AI-powered platforms to accelerate the discovery of next-generation oncology therapeutics. As the Phase 1 program continues, additional clinical data will further evaluate the therapy’s safety profile and antitumor activity while supporting future development strategies for patients with mesothelioma and other Hippo-driven cancers.
Advertisement
Accelerating AI-Driven Innovation in Oncology Drug Discovery
The presentation of ISM6331 at ESMO 2026 further strengthens Insilico Medicine’s position as a leader in AI-powered biopharmaceutical innovation. By combining generative artificial intelligence, advanced medicinal chemistry, and precision oncology research, the company continues to demonstrate how AI can significantly accelerate the identification and clinical development of novel cancer therapies. The ongoing global Phase 1 clinical trial represents another important step toward expanding treatment options for patients with aggressive solid tumors that currently have limited therapeutic choices. As AI continues transforming pharmaceutical research and development, ISM6331 highlights the growing potential of intelligent drug design to address complex oncogenic pathways and improve future cancer care through innovative precision medicines.
Source: Insilico Medicine press release
